Value of methylation markers in colorectal cancer (Review)
- Authors:
- Can Kong
- Tao Fu
-
Affiliations: Department of Gastrointestinal Surgery II, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China - Published online on: June 30, 2021 https://doi.org/10.3892/or.2021.8128
- Article Number: 177
This article is mentioned in:
Abstract
 |
|
Liu Y, Guo F, Zhu X, Guo W, Fu T and Wang W: Death domain-associated protein promotes colon cancer metastasis through direct interaction with ZEB1. J Cancer. 11:750–758. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang C, Liu Y, Guo W, Zhu X, Ahuja N and Fu T: MAPT promoter CpG island hypermethylation is associated with poor prognosis in patients with stage II colorectal cancer. Cancer Manag Res Volume. 11:7337–7343. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Jones PA, Ohtani H, Chakravarthy A and De Carvalho DD: Epigenetic therapy in immune-oncology. Nat Rev Cancer. 19:151–161. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bates SE: Epigenetic therapies for cancer. N Engl J Med. 383:650–663. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Deans C and Maggert KA: What do you mean, ‘epigenetic’? Genetics. 199:887–896. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Al AN, Tupper C and Jialal I: Genetics, epigenetic mechanism. 2021.PubMed/NCBI | |
|
Okugawa Y, Grady WM and Goel A: Epigenetic alterations in colorectal cancer: Emerging biomarkers. Gastroenterology. 149:1204–1225.e12. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
van der Pol Y and Mouliere F: Toward the early detection of cancer by decoding the epigenetic and environmental fingerprints of cell-free DNA. Cancer Cell. 36:350–368. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Luo H, Wei W, Ye Z, Zheng J and Xu RH: Liquid biopsy of methylation biomarkers in cell-free DNA. Trends Mol Med. 27:482–500. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Peterse E, Meester R, de Jonge L, Omidvari AH, Alarid-Escudero F, Knudsen AB, Zauber AG and Lansdorp-Vogelaar I: Comparing the cost-effectiveness of innovative colorectal cancer screening tests. J Natl Cancer Inst. 113:154–161. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Komor MA, Bosch LJ, Bounova G, Bolijn AS, Delis-van DP, Rausch C, Hoogstrate Y, Stubbs AP, de Jong M, Jenster G, et al: Consensus molecular subtype classification of colorectal adenomas. J Pathol. 246:266–276. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Locke WJ, Guanzon D, Ma C, Liew YJ, Duesing KR, Fung K and Ross JP: DNA methylation cancer biomarkers: Translation to the clinic. Front Genet. 10:11502019. View Article : Google Scholar : PubMed/NCBI | |
|
Tse JWT, Jenkins LJ, Chionh F and Mariadason JM: Aberrant DNA methylation in colorectal cancer: What should we target? Trends Cancer. 3:698–712. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Carethers JM: Fecal DNA testing for colorectal cancer screening. Annu Rev Med. 71:59–69. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Iyer GR and Hasan Q: Alteration of methylation status in archival DNA samples: A qualitative assessment by methylation specific polymerase chain reaction. Environ Mol Mutagen. 61:837–842. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Fu T, Sharmab A, Xie F, Liu Y, Li K, Wan W, Baylin SB, Wolfgang CL and Ahuja N: Methylation of MGMT is associated with poor prognosis in patients with stage III duodenal adenocarcinoma. PLoS One. 11:e1629292016. View Article : Google Scholar : PubMed/NCBI | |
|
Azuara D, Ausso S, Rodriguez-Moranta F, Guardiola J, Sanjuan X, Lobaton T, Boadas J, Piqueras M, Monfort D, Guino E, et al: New methylation biomarker panel for early diagnosis of dysplasia or cancer in high-risk inflammatory bowel disease patients. Inflamm Bowel Dis. 24:2555–2564. 2018.PubMed/NCBI | |
|
Pichon F, Shen Y, Busato F, P JS, Jacquelin B, Grand RL, Deleuze JF, Muller-Trutwin M and Tost J: Analysis and annotation of DNA methylation in two nonhuman primate species using the Infinium Human Methylation 450K and EPIC BeadChips. Epigenomics. 13:169–186. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Li D, Guo J, Wang S, Zhu L and Shen Z: Identification of novel methylated targets in colorectal cancer by microarray analysis and construction of co-expression network. Oncol Lett. 14:2643–2648. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wagner I and Capesius I: Determination of 5-methylcytosine from plant DNA by high-performance liquid chromatography. Biochim Biophys Acta. 654:52–56. 1981. View Article : Google Scholar : PubMed/NCBI | |
|
Li S and Tollefsbol TO: DNA methylation methods: Global DNA methylation and methylomic analyses. Methods. 187:28–43. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kang B, Lee HS, Jeon SW, Park SY, Choi GS, Lee WK, Heo S, Lee DH and Kim DS: Progressive alteration of DNA methylation of Alu, MGMT, MINT2, and TFPI2 genes in colonic mucosa during colorectal cancer development. Cancer Biomark. Jun 5–2021.(Epub ahead of print). doi: 10.3233/CBM-203259. View Article : Google Scholar | |
|
Naini MA, Kavousipour S, Hasanzarini M, Nasrollah A, Monabati A and Mokarram P: O6-Methyguanine-DNA Methyl Transferase (MGMT) promoter methylation in serum DNA of Iranian patients with colorectal cancer. Asian Pac J Cancer Prev. 19:1223–1227. 2018.PubMed/NCBI | |
|
Kerachian MA and Kerachian M: Long interspersed nucleotide element-1 (LINE-1) methylation in colorectal cancer. Clin Chim Acta. 488:209–214. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Chen PM and Liu RB: Advance in plasma SEPT9 gene methylation assay for colorectal cancer early detection. World J Gastrointest Oncol. 10:15–22. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sun J, Zheng M, Li Y and Zhang S: Structure and function of Septin 9 and its role in human malignant tumors. World J Gastro Oncol. 12:619–631. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tóth K, Galamb O, Spisák S, Wichmann B, Sipos F, Valcz G, Leiszter K, Molnár B and Tulassay Z: The influence of methylated septin 9 gene on RNA and protein level in colorectal cancer. Pathol Oncol Res. 17:503–509. 2011. View Article : Google Scholar | |
|
Wasserkort R, Kalmar A, Valcz G, Spisak S, Krispin M, Toth K, Tulassay Z, Sledziewski AZ and Molnar B: Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island. BMC Cancer. 13:3982013. View Article : Google Scholar : PubMed/NCBI | |
|
Hu J, Hu B, Gui YC, Tan ZB and Xu JW: Diagnostic value and clinical significance of methylated SEPT9 for colorectal cancer: A meta-analysis. Med Sci Monit. 25:5813–5822. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, Castaños-Vélez E, Blumenstein BA, Rosch T, Osborn N, et al: Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 63:317–325. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Song L, Li Y, Jia J, Zhou G, Wang J, Kang Q, Jin P, Sheng J, Cai G, Cai S and Han X: Algorithm Optimization in Methylation Detection with Multiple RT-qPCR. PLoS One. 11:e1633332016. View Article : Google Scholar | |
|
Choi Y, Kim H, Chung H, Hwang JS, Shin JA, Han IO and Oh ES: Syndecan-2 regulates cell migration in colon cancer cells through Tiam1-mediated Rac activation. Biochem Biophys Res Commun. 391:921–925. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao G, Ma Y, Li H, Li S, Zhu Y, Liu X, Xiong S, Liu Y, Miao J, Fei S, et al: A novel plasma based early colorectal cancer screening assay base on methylated SDC2 and SFRP2. Clin Chim Acta. 503:84–89. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Han YD, Oh TJ, Chung TH, Jang HW, Kim YN, An S and Kim NK: Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. Clin Epigenetics. 11:512019. View Article : Google Scholar : PubMed/NCBI | |
|
Oh TJ, Oh HI, Seo YY, Jeong D, Kim C, Kang HW, Han YD, Chung HC, Kim NK and An S: Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clin Epigenetics. 9:1262017. View Article : Google Scholar : PubMed/NCBI | |
|
Su WC, Kao WY, Chang TK, Tsai HL, Huang CW, Chen YC, Li CC, Hsieh YC, Yeh HJ, Chang CC, et al: Stool DNA test targeting methylated syndecan-2 (SDC2) as a noninvasive screening method for colorectal cancer. Biosci Rep. 29(41): BSR202019302021. View Article : Google Scholar | |
|
Kim CW, Kim H, Kim HR, Kye BH, Kim HJ, Min BS, Oh TJ, An S and Lee SH: Colorectal cancer screening using a stool DNA-based SDC2 methylation test: A multicenter, prospective trial. BMC Gastroenterol. 21:1732021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao G, Liu X, Liu Y, Ma Y, Yang J, Li H, Xiong S, Fei S, Zheng M and Zhao X: MethylatedSFRP2 and SDC2 in stool specimens for Colorectal Cancer early detection: A cost-effective strategy for Chinese population. J Cancer. 12:2665–2672. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN, Issa JP, Sidransky D, Baylin SB and Herman JG: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 60:2368–2371. 2000.PubMed/NCBI | |
|
Shima K, Morikawa T, Baba Y, Nosho K, Suzuki M, Yamauchi M, Hayashi M, Giovannucci E, Fuchs CS and Ogino S: MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control. 22:301–309. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sartore-Bianchi A, Amatu A, Bonazzina E, Stabile S, Giannetta L, Cerea G, Schiavetto I, Bencardino K, Funaioli C, Ricotta R, et al: Pooled analysis of clinical outcome of patients with chemorefractory metastatic colorectal cancer treated within phase I/II clinical studies based on individual biomarkers of susceptibility: A single-institution experience. Target Oncol. 12:525–533. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Freitas M, Ferreira F, Carvalho S, Silva F, Lopes P, Antunes L, Salta S, Diniz F, Santos LL, Videira JF, et al: A novel DNA methylation panel accurately detects colorectal cancer independently of molecular pathway. J Transl Med. 16:452018. View Article : Google Scholar : PubMed/NCBI | |
|
Qu X, Zhai Y, Wei H, Zhang C, Xing G, Yu Y and He F: Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem. 229:35–44. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Vaes N, Schonkeren SL, Rademakers G, Holland AM, Koch A, Gijbels MJ, Keulers TG, de Wit M, Moonen L, Van der Meer J, et al: Loss of enteric neuronal Ndrg4 promotes colorectal cancer via increased release of Nid1 and Fbln2. EMBO Rep. 22:e519132021. View Article : Google Scholar : PubMed/NCBI | |
|
Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA and Berger BM: Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 370:1287–1297. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bagheri H, Mosallaei M, Bagherpour B, Khosravi S, Salehi AR and Salehi R: TFPI2 and NDRG4 gene promoter methylation analysis in peripheral blood mononuclear cells are novel epigenetic noninvasive biomarkers for colorectal cancer diagnosis. J Gene Med. 22:e31892020. View Article : Google Scholar : PubMed/NCBI | |
|
Rademakers G, Massen M, Koch A, Draht MX, Buekers N, Wouters K, Vaes N, De Meyer T, Carvalho B, Meijer GA, et al: Identification of DNA methylation markers for early detection of CRC indicates a role for nervous system-related genes in CRC. Clin Epigenetics. 13:802021. View Article : Google Scholar : PubMed/NCBI | |
|
Mojtabanezhad Shariatpanahi A, Yassi M, Nouraie M, Sahebkar A, Varshoee Tabrizi F and Kerachian MA: The importance of stool DNA methylation in colorectal cancer diagnosis: A meta-analysis. PLoS One. 13:e2007352018. View Article : Google Scholar : PubMed/NCBI | |
|
Lu H, Huang S, Zhang X, Wang D, Zhang X, Yuan X, Zhang Q and Huang Z: DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA. Oncol Lett. 8:1751–1756. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao W, Zhao H, Dong W, Li Q, Zhu J, Li G, Zhang S and Ye M: Quantitative detection of methylated NDRG4 gene as a candidate biomarker for diagnosis of colorectal cancer. Oncol Lett. 9:1383–1387. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang C, Ouyang C, Cho M, Ji J, Sandhu J, Goel A, Kahn M and Fakih M: Wild-type APC is associated with poor survival in metastatic microsatellite stable colorectal cancer. Oncologist. 26:208–214. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Matthaios D, Balgkouranidou I, Karayiannakis A, Bolanaki H, Xenidis N, Amarantidis K, Chelis L, Romanidis K, Chatzaki A, Lianidou E, et al: Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer. Oncol Lett. 12:748–756. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Aitchison A, Hakkaart C, Day RC, Morrin HR, Frizelle FA and Keenan JI: APC mutations are not confined to hotspot regions in early-onset colorectal cancer. Cancers. 12:38292020. View Article : Google Scholar : PubMed/NCBI | |
|
Nunes S, Moreira-Barbosa C, Salta S, Palma De Sousa S, Pousa I, Oliveira J, Soares M, Rego L, Dias T, Rodrigues J, et al: Cell-free DNA methylation of selected genes allows for early detection of the major cancers in women. Cancers. 10:3572018. View Article : Google Scholar : PubMed/NCBI | |
|
Liang T, Wang H, Zheng Y, Cao Y, Wu X, Zhou X and Dong S: APC hypermethylation for early diagnosis of colorectal cancer: A meta-analysis and literature review. Oncotarget. 8:46468–46479. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Loh K, Chia JA, Greco S, Cozzi SJ, Buttenshaw RL, Bond CE, Simms LA, Pike T, Young JP, Jass JR, et al: Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer development. Genes Chromosomes Cancer. 47:449–460. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Houshmand M, Abbaszadegan MR and Kerachian MA: Assessment of bone morphogenetic protein 3 methylation in Iranian patients with colorectal cancer. Middle East J Dig Dis. 9:158–163. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Rokni P, Shariatpanahi AM, Sakhinia E and Kerachian MA: BMP3 promoter hypermethylation in plasma-derived cell-free DNA in colorectal cancer patients. Genes Genom. 40:423–428. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kisiel JB, Yab TC, Nazer HF, Taylor WR, Garrity-Park MM, Sandborn WJ, Loftus EV, Wolff BG, Smyrk TC, Itzkowitz SH, et al: Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 37:546–554. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Redwood DG, Asay ED, Blake ID, Sacco PE, Christensen CM, Sacco FD, Tiesinga JJ, Devens ME, Alberts SR, Mahoney DW, et al: Stool DNA testing for screening detection of colorectal neoplasia in alaska native people. Mayo Clin Proc. 91:61–70. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
El BK, Tariq K, Himri I, Jaafari A, Smaili W, Kandhro AH, Gouri A and Ghazi B: Decoding colorectal cancer epigenomics. Cancer Genet. 220:49–76. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Baek YH, Chang E, Kim YJ, Kim BK, Sohn JH and Park DI: Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients. Dis Colon Rectum. 52:1452–1459, 1459-1463. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Grady WM, Yu M and Markowitz SD: Epigenetic alterations in the gastrointestinal tract: Current and emerging use for biomarkers of cancer. Gastroenterology. 160:690–709. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Laugsand EA, Brenne SS and Skorpen F: DNA methylation markers detected in blood, stool, urine, and tissue in colorectal cancer: A systematic review of paired samples. Int J Colorectal Dis. 36:239–251. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Musher BL, Melson JE, Amato G, Chan D, Hill M, Khan I, Kochuparambil ST, Lyons SE, Orsini JJ Jr, Pedersen SK, et al: Evaluation of circulating tumor DNA for methylated BCAT1 and IKZF1 to detect recurrence of stage II/stage III colorectal cancer (CRC). Cancer Epidemiol Biomarkers Prev. 29:2702–2709. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Rasmussen SL, Krarup HB, Sunesen KG, Johansen MB, Stender MT, Pedersen IS, Madsen PH and Thorlacius-Ussing O: Hypermethylated DNA, a circulating biomarker for colorectal cancer detection. PLoS One. 12:e1808092017. View Article : Google Scholar | |
|
Yu J, Xie Y, Li M, Zhou F, Zhong Z, Liu Y, Wang F and Qi J: Association between SFRP promoter hypermethylation and different types of cancer: A systematic review and meta-analysis. Oncol Lett. 18:3481–3492. 2019.PubMed/NCBI | |
|
Hu H, Wang T, Pan R, Yang Y, Li B, Zhou C, Zhao J, Huang Y and Duan S: Hypermethylated promoters of secreted frizzled-related protein genes are associated with colorectal cancer. Pathol Oncol Res. 25:567–575. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hattori N, Sako M, Kimura K, Iida N, Takeshima H, Nakata Y, Kono Y and Ushijima T: Novel prodrugs of decitabine with greater metabolic stability and less toxicity. Clin Epigenetics. 11:1112019. View Article : Google Scholar : PubMed/NCBI | |
|
Boughanem H, Cabrera-Mulero A, Hernandez-Alonso P, Clemente-Postigo M, Casanueva FF, Tinahones FJ, Morcillo S, Crujeiras AB and Macias-Gonzalez M: Association between variation of circulating 25-OH vitamin D and methylation of secreted frizzled-related protein 2 in colorectal cancer. Clin Epigenetics. 12:832020. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar A, Gosipatala SB, Pandey A and Singh P: Prognostic relevance of SFRP1 gene promoter methylation in colorectal carcinoma. Asian Pac J Cancer Prev. 20:1571–1577. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bagci B, Sari M, Karadayi K, Turan M, Ozdemir O and Bagci G: KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients. Cancer Biomark. 17:133–143. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
van Loon K, Huijbers E and Griffioen AW: Secreted frizzled-related protein 2: A key player in noncanonical Wnt signaling and tumor angiogenesis. Cancer Metastasis Rev. 40:191–203. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Karam RA, Zidan HE, Abd Elrahman TM, Badr SA and Amer SA: Study of p16 promoter methylation in Egyptian colorectal cancer patients. J Cell Biochem. 120:8581–8587. 2018. View Article : Google Scholar | |
|
Ye X, Mo M, Xu S, Yang Q, Wu M, Zhang J, Chen B, Li J, Zhong Y, Huang Q and Cai C: The hypermethylation of p16 gene exon 1 and exon 2: Potential biomarkers for colorectal cancer and are associated with cancer pathological staging. BMC Cancer. 18:10232018. View Article : Google Scholar : PubMed/NCBI | |
|
Lee M, Sup HW, Kyoung KO, Hee SS, Sun CM, Lee SN and Koo H: Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer. Pathol Res Pract. 202:415–424. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SH, Park KH, Shin SJ, Lee KY, Kim TI, Kim NK, Rha SY, Roh JK and Ahn JB: p16 hypermethylation and KRAS mutation are independent predictors of cetuximab plus FOLFIRI chemotherapy in patients with metastatic colorectal cancer. Cancer Res Treat. 48:208–215. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Shademan M, Zare K, Zahedi M, Mosannen MH, Bagheri HH, Ghaffarzadegan K, Goshayeshi L and Dehghani H: Promoter methylation, transcription, and retrotransposition of LINE-1 in colorectal adenomas and adenocarcinomas. Cancer Cell Int. 20:4262020. View Article : Google Scholar : PubMed/NCBI | |
|
Schauer SN, Carreira PE, Shukla R, Gerhardt DJ, Gerdes P, Sanchez-Luque FJ, Nicoli P, Kindlova M, Ghisletti S, Santos AD, et al: L1 retrotransposition is a common feature of mammalian hepatocarcinogenesis. Genome Res. 28:639–653. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Baba Y, Yagi T, Sawayama H, Hiyoshi Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N and Baba H: Long interspersed element-1 methylation level as a prognostic biomarker in gastrointestinal cancers. Digestion. 97:26–30. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang AC, Buckingham L, Bishehsari F, Sutherland S, Ma K and Melson JE: Correlation of LINE-1 hypomethylation with size and pathologic extent of dysplasia in colorectal tubular adenomas. Clin Transl Gastroenterol. 12:e003692021. View Article : Google Scholar : PubMed/NCBI | |
|
Barchitta M, Quattrocchi A, Maugeri A, Vinciguerra M, Agodi A and Katoh M: LINE-1 hypomethylation in blood and tissue samples as an epigenetic marker for cancer risk: A systematic review and meta-analysis. PLoS One. 9:e1094782014. View Article : Google Scholar : PubMed/NCBI | |
|
Ye D, Jiang D, Li Y, Jin M and Chen K: The role of LINE-1 methylation in predicting survival among colorectal cancer patients: A meta-analysis. Int J Clin Oncol. 22:749–757. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Boughanem H, Martin-Nunez GM, Torres E, Arranz-Salas I, Alcaide J, Morcillo S, Tinahones FJ, Crujeiras AB and Macias-Gonzalez M: Impact of tumor LINE-1 methylation level and neoadjuvant treatment and its association with colorectal cancer survival. J Pers Med. 10:2192020. View Article : Google Scholar : PubMed/NCBI | |
|
Nagai Y, Sunami E, Yamamoto Y, Hata K, Okada S, Murono K, Yasuda K, Otani K, Nishikawa T, Tanaka T, et al: LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer. Oncotarget. 8:11906–11916. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Symonds EL, Pedersen SK, Murray DH, Jedi M, Byrne SE, Rabbitt P, Baker RT, Bastin D and Young GP: Circulating tumour DNA for monitoring colorectal cancer-a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection. Clin Epigenetics. 10:632018. View Article : Google Scholar : PubMed/NCBI | |
|
Javierre BM, Rodriguez-Ubreva J, Al-Shahrour F, Corominas M, Grana O, Ciudad L, Agirre X, Pisano DG, Valencia A, Roman-Gomez J, et al: Long-range epigenetic silencing associates with deregulation of Ikaros targets in colorectal cancer cells. Mol Cancer Res. 9:1139–1151. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mitchell S, Ho T, Brown G, Baker R, Thomas M, McEvoy A, Xu Z, Ross J, Lockett T, Young G, et al: Evaluation of methylation biomarkers for detection of circulating tumor DNA and application to colorectal cancer. Genes (Basel). 7:1252016. View Article : Google Scholar : PubMed/NCBI | |
|
Pedersen SK, Symonds EL, Baker RT, Murray DH, McEvoy A, Van Doorn SC, Mundt MW, Cole SR, Gopalsamy G, Mangira D, et al: Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia. BMC Cancer. 15:6542015. View Article : Google Scholar : PubMed/NCBI | |
|
Symonds EL, Pedersen SK, Baker RT, Murray DH, Gaur S, Cole SR, Gopalsamy G, Mangira D, LaPointe LC and Young GP: A blood test for methylated BCAT1 and IKZF1 vs. a fecal immunochemical test for detection of colorectal neoplasia. Clin Transl Gastroen. 7:e1372016. View Article : Google Scholar : PubMed/NCBI | |
|
Symonds EL, Pedersen SK, Murray D, Byrne SE, Roy A, Karapetis C, Hollington P, Rabbitt P, Jones FS, LaPointe L, et al: Circulating epigenetic biomarkers for detection of recurrent colorectal cancer. Cancer. 126:1460–1469. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Murray DH, Symonds EL, Young GP, Byrne S, Rabbitt P, Roy A, Cornthwaite K, Karapetis CS and Pedersen SK: Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival. J Cancer Res Clin. 144:1741–1750. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Pasha HF, Mohamed RH and Radwan MI: RASSF1A and SOCS1 genes methylation status as a noninvasive marker for hepatocellular carcinoma. Cancer Biomark. 24:241–247. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Blanchard TG, Czinn SJ, Banerjee V, Sharda N, Bafford AC, Mubariz F, Morozov D, Passaniti A, Ahmed H and Banerjee A: Identification of cross talk between FoxM1 and RASSF1A as a therapeutic target of colon cancer. Cancers (Basel). 11:1992019. View Article : Google Scholar : PubMed/NCBI | |
|
Sanduleanu S and Siersema PD: Laterally spreading tumor through the magnifying glass: We only see what we know. Endoscopy. 48:421–423. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ni HB, Wang FY, Xu J, He XJ, Chen J, Wu Q, Wu JF and Sun YS: Screening and identification of a tumor specific methylation phenotype in the colorectal laterally spreading tumor. Eur Rev Med Pharmacol Sci. 21:2611–2616. 2017.PubMed/NCBI | |
|
Sun X, Yuan W, Hao F and Zhuang W: Promoter methylation of RASSF1A indicates prognosis for patients with stage II and III colorectal cancer treated with oxaliplatin-based chemotherapy. Med Sci Monitor. 23:5389–5395. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hu F, Chen L, Bi MY, Zheng L, He JX, Huang YZ, Zhang Y, Zhang XL, Guo Q, Luo Y, et al: Potential of RASSF1A promoter methylation as a biomarker for colorectal cancer: Meta-analysis and TCGA analysis. Pathol Res Pract. 216:1530092020. View Article : Google Scholar : PubMed/NCBI | |
|
Shi B, Chu J, Gao Q and Tian T: Promoter methylation of human mutL homolog 1 and colorectal cancer risk: A meta-analysis. J Cancer Res Ther. 14:851–855. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sun SY, Hu XT, Yu XF, Zhang YY, Liu XH, Liu YH, Wu SH, Li YY, Cui SX and Qu XJ: Nuclear translocation of ATG5 induces DNA mismatch repair deficiency (MMR-D)/microsatellite instability (MSI) via interacting with Mis18alpha in colorectal cancer. Br J Pharmacol. 178:2351–2369. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Lu Y, Xie Z and Wang K: Relationship between human mutL Homolog 1 (hMLH1) hypermethylation and colorectal cancer: A meta-analysis. Med Sci Monitor. 23:3026–3038. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chung C: Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation. J Oncol Pharm Pract. 107815522110055252021.PubMed/NCBI | |
|
Fu T, Liu Y, Li K, Wan W, Pappou EP, Iacobuzio-Donahue CA, Kerner Z, Baylin SB, Wolfgang CL and Ahuja N: Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients. Oncotarget. 7:86480–86489. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kuan JC, Wu CC, Sun CA, Chu CM, Lin FG, Hsu CH, Kan PC, Lin SC, Yang T and Chou YC: DNA methylation combinations in adjacent normal colon tissue predict cancer recurrence: Evidence from a clinical cohort study. PLoS One. 10:e1233962015. View Article : Google Scholar : PubMed/NCBI | |
|
Maier S, Dahlstroem C, Haefliger C, Plum A and Piepenbrock C: Identifying DNA methylation biomarkers of cancer drug response. Am J Pharmacogenomics. 5:223–232. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Jover R, Nguyen TP, Perez-Carbonell L, Zapater P, Paya A, Alenda C, Rojas E, Cubiella J, Balaguer F, Morillas JD, et al: 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology. 140:1174–1181. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Oliver JA, Ortiz R, Jimenez-Luna C, Cabeza L, Perazzoli G, Caba O, Mesas C, Melguizo C and Prados J: MMR-proficient and MMR-deficient colorectal cancer cells: 5-Fluorouracil treatment response and correlation to CD133 and MGMT expression. J Biosci. 45:1212020. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng X, Xu X, Chen D, Zhao F and Wang W: Therapeutic potential of targeting the Wnt/beta-catenin signaling pathway in colorectal cancer. Biomed Pharmacother. 110:473–481. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Gujral TS, Chan M, Peshkin L, Sorger PK, Kirschner MW and MacBeath G: A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell. 159:844–856. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Qi L, Chen J, Zhou B, Xu K, Wang K, Fang Z, Shao Y, Yuan Y, Zheng S and Hu W: HomeoboxC6 promotes metastasis by orchestrating the DKK1/Wnt/β-catenin axis in right-sided colon cancer. Cell Death Dis. 12:3372021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Liu HL, Zhao FH, Jiao ZX, Wang JS and Dang YM: Wnt5a plays controversial roles in cancer progression. Chin Med Sci J. 35:357–365. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SH, Park KH, Shin SJ, Lee KY, Kim TI, Kim NK, Rha SY and Ahn JB: CpG island methylator phenotype and methylation of Wnt pathway genes together predict survival in patients with colorectal cancer. Yonsei Med J. 59:5882018. View Article : Google Scholar : PubMed/NCBI | |
|
Hibi K, Mizukami H, Goto T, Kitamura Y, Sakata M, Saito M, Ishibashi K, Kigawa G, Nemoto H and Sanada Y: WNT5A gene is aberrantly methylated from the early stages of colorectal cancers. Hepatogastroenterology. 56:1007–1009. 2009.PubMed/NCBI | |
|
Jiang G, Lin J, Wang W, Sun M, Chen K and Wang F: WNT5A promoter methylation is associated with better responses and longer progression-free survival in colorectal cancer patients treated with 5-fluorouracil-based chemotherapy. Genet Test Mol Bioma. 21:74–79. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Draht M, Goudkade D, Koch A, Grabsch HI, Weijenberg MP, van Engeland M, Melotte V and Smits KM: Prognostic DNA methylation markers for sporadic colorectal cancer: A systematic review. Clin Epigenetics. 10:352018. View Article : Google Scholar : PubMed/NCBI | |
|
Nagaraju GP, Kasa P, Dariya B, Surepalli N, Peela S and Ahmad S: Epigenetics and therapeutic targets in gastrointestinal malignancies. Drug Discov Today. S1359-6446(21)00202-6. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Jung G, Hernández-Illán E, Moreira L, Balaguer F and Goel A: Epigenetics of colorectal cancer: Biomarker and therapeutic potential. Nat Rev Gastro Hepat. 17:111–130. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cervena K, Siskova A, Buchler T, Vodicka P and Vymetalkova V: Methylation-based therapies for colorectal cancer. Cells-Basel. 9:15402020. View Article : Google Scholar : PubMed/NCBI | |
|
Singh M, Kumar V, Sehrawat N, Yadav M, Chaudhary M, Upadhyay SK, Kumar S, Sharma V, Kumar S, Dilbaghi N and Sharma AK: Current paradigms in epigenetic anticancer therapeutics and future challenges. Semin Cancer Biol. S1044-579X(21)00063-8. 2021. View Article : Google Scholar | |
|
Wei T, Lin Y, Tang S, Luo C, Tsai C, Shun C and Chen C: Metabolic targeting of HIF-1α potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer. Oncogene. 39:414–427. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Su X, Dai L, Chen N, Fang C, Dong Z, Fu J, Yu Y, Wang W, Zhang H, et al: Temporal DNA methylation pattern and targeted therapy in colitis-associated cancer. Carcinogenesis. 41:235–244. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Pechalrieu D, Etievant C and Arimondo PB: DNA methyltransferase inhibitors in cancer: From pharmacology to translational studies. Biochem Pharmacol. 129:1–13. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kisiel JB, Klepp P, Allawi HT, Taylor WR, Giakoumopoulos M, Sander T, Yab TC, Moum BA, Lidgard GP, Brackmann S, et al: Analysis of DNA methylation at specific loci in stool samples detects colorectal cancer and high-grade dysplasia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 17:914–921.e5. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Sun H, Tang W, Zhou L, Xie X, Qu Z, Chen M, Wang S, Yang T, Dai Y, et al: DNA methylation biomarkers in stool for early screening of colorectal cancer. J Cancer. 10:5264–5271. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pan Y, Liu G, Zhou F, Su B and Li Y: DNA methylation profiles in cancer diagnosis and therapeutics. Clin Exp Med. 18:1–14. 2018. View Article : Google Scholar : PubMed/NCBI |
